Service de psychiatrie (Pr Adès)
Colombes, 92700, France
NCT Number: NCT00798109
Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Colombes, 92700, France
Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.
330 patients with schizophrenia and cannabis abuse or dependence (according to DSM-IV criteria) are randomly assigned to 4 motivational interview during one month or usual intensive treatment. Treatment is conducted in outpatient which are evaluated at the inclusion and at 6 month with Time-Line Follow Bach for the consumption, PANSS score, number of relapse…). A outcome measure was urinalysis results providing an objective measure of cannabis use throughout the six month of the trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One hour of motivational therapy each weak during 4 weeks
Patients received at least six hour of usual therapy, as in the experimental group
Time frame: inclusion, 3 month, 6 month, 12 month
Time frame: inclusion, 3 month, 6 month, 12 month. Only inclusion and 6 month for urianalysis
PANSS : global, positive, negative, general scores
Assistance Publique - Hôpitaux de Paris
Other
An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease
Acronym: SCHIZOCAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05380583
Alcohol, Bipolar Disorder
Belmont, Massachusetts, United States
View Trial DetailsNCT00982982
Chemically-Induced Disorders, Marijuana Abuse
West Haven, Connecticut, United States
View Trial DetailsNCT04284813
Alcohol, Alcohol Use Disorder
Belmont, Massachusetts, United States
View Trial DetailsNCT01639872
Cannabis Abuse, Cannabis Dependence
Garden Grove, California, United States
View Trial Details